Leukocare AG

Leukocare AG is a provider of drug product development services, with a focus on data science-driven approaches to formulation and predictive stability for biologics. The company supports biopharmaceutical companies in developing complex biologics, including bispecific antibodies, multispecific antibodies, fusion proteins, and high-concentration formulations.

Leukocare AG is a provider of drug product development services. In July 2026, it announced a collaboration with Celonic AG to support biopharmaceutical companies developing complex biologics. The collaboration combines Celonic's expertise in cell line development, drug substance process development, intensified bioprocessing, and GMP manufacturing with Leukocare's data science-driven approach to drug product development. Additionally, Leukocare announced the appointment of Dr. Cornelius Pompe as its new Chief Operating Officer (COO) and Board member. Cornelius Pompe joined Leukocare's management team in 2021, first as Vice President Research & Development and subsequently as Chief Development Officer (CDO).

1. 1Leukocare | SMART Formulation & Predictive Stability for Biologicsleukocare.com
2. 2Celonic AG and Leukocare AG Announce Development Collaboration to Support Joint Clients with Complex Biologics and Advanced Drug Product Profiles - Leukocare AGleukocare.com
3. 3We congratulate Cornelius Pompe as our new COO and welcome him as new Board member - Leukocare AGleukocare.com
4. 4About Leukocare | Biologics Formulation Experts & Innovatorsleukocare.com